- Conditions
- Epistaxis, Blood Pressure
- Interventions
- Oxymetazoline 0.05%, Phenylephrine 0.25%, Lidocaine 1% plus epinephrine 1:100,000, Bacteriostatic 0.9% NaCL
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 252
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy Participants
- Interventions
- Abiraterone acetate, 250 mg (uncoated, current commercial tablet), Abiraterone acetate, 500 mg (coated, reformulated tablet), Abiraterone acetate, 250 mg (coated, reformulated tablet), Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
- Interventions
- NKTR-118, moxifloxacin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Anesthesia
- Interventions
- Tetracaine HCl 3% and Oxymetazoline HCl 0.05%, Tetracaine HCl 3%, Placebo
- Drug
- Lead sponsor
- St. Renatus, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Buffalo, New York • Salt Lake City, Utah
- Conditions
- Healthy Subjects
- Interventions
- 1.25 mg/kg BL-8040 + BL-8040-matching placebo, 2 mg/kg BL-8040, BL-8040-matching placebo, 400 mg Moxifloxacin (1x400 mg tablet)
- Drug
- Lead sponsor
- BioLineRx, Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Healthy Participants
- Interventions
- LY4100511, Rabeprazole
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 2
- States / cities
- Miami, Florida • Knoxville, Tennessee
- Conditions
- Cardiac Repolarization in Healthy Subjects
- Interventions
- ZTI-01, Moxifloxacin 400mg, Placebo IV
- Drug · Other
- Lead sponsor
- Nabriva Therapeutics AG
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Idiopathic Thrombocytopenia Purpura
- Interventions
- E5501, Drug: E5501
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- AZD3355, placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Cesarean Delivery
- Interventions
- Metoclopramide, Phenylephrine infusion, Combination Group
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Dental Anesthesia, Nasal Surgical Procedures, Intranasal Drug Administration
- Interventions
- Oxymetazoline
- Drug
- Lead sponsor
- Richard Cartabuke
- Other
- Eligibility
- 2 Years to 12 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Vasoconstriction, Vasodilation
- Interventions
- Handgrip Exercise Training, Acetylcholine, Adenosine Triphosphate, Atropine, Phenylephrine, Sodium Nitroprusside
- Other · Drug
- Lead sponsor
- Colorado State University
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Stress Disorders, Post-Traumatic
- Interventions
- Microneurography, Combat virtual reality video clip, Handgrip Exercise, Cold Pressor Test (CPT), Sodium Nitroprusside (SNP), Phenylephrine, Losartan, Atenolol, Transcutaneous Vagal Nerve Stimulation (tVNS), Sham Transcutaneous Vagal Nerve Stimulation (tVNS)
- Procedure · Behavioral · Drug + 1 more
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Lung; Node
- Interventions
- RAB via the Monarch platform, RAB via the ION platform
- Procedure
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Anesthesia
- Interventions
- Tetracaine HCl 3% and Oxymetazoline HCl 0.05%, Placebo
- Drug
- Lead sponsor
- St. Renatus, LLC
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 2
- States / cities
- Loma Linda, California • Fort Collins, Colorado
- Conditions
- Acute Kidney Injury
- Interventions
- Vasopressin, Phenylephrine
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Gulf War Syndrome, Chronic Fatigue Syndrome, Post-Traumatic Stress Disorder
- Interventions
- Graded dobutamine infusions, Graded phenylephrine injections, Psychosocial challenge involving socioevaluative public speaking
- Drug · Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- Not listed
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- East Orange, New Jersey
- Conditions
- Healthy Subjects
- Interventions
- placebo, lorazepam, GW876008
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Prolonged QTc Interval
- Interventions
- Estetrol 20 mg, Estetrol 100 mg, Placebo, Moxifloxacin 400 mg
- Drug
- Lead sponsor
- Estetra
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Mydriasis
- Interventions
- MDD-administered EYN-1601, Phenylephrine 2.5% Eyedrop, Phenylephrine 10% Eyedrop
- Combination Product · Drug
- Lead sponsor
- Eyenovia Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Artesia, California
- Conditions
- Prematurity, VLBW - Very Low Birth Weight Infant
- Interventions
- Prepod, Joint compression exercises
- Other · Procedure
- Lead sponsor
- Asante Health System
- Other
- Eligibility
- 32 Weeks to 36 Weeks
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Medford, Oregon
- Conditions
- Cataract
- Interventions
- Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}, Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}
- Drug
- Lead sponsor
- Inder Paul Singh, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Venice, Florida • Racine, Wisconsin
- Conditions
- Assess Phenylephrine on EVP and IOP
- Interventions
- Phenylephrine 2.5%
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Postural Orthostatic Tachycardia Syndrome, Postural Tachycardia Syndrome, Tachycardia, Arrhythmias, Cardiac, Autonomic Nervous System Diseases, Orthostatic Intolerance, Cardiovascular Diseases, Primary Dysautonomias
- Interventions
- phenylephrine, isoproterenol, 25 micro-Ci of radiation, Posture study with blood samples, 24-hour heart rhythm and blood pressure monitoring, Quantitative Axonal Sudomotor Reflex Testing, Autonomic function tests, Rebreathing test, Assessment of splanchnic capacitance, microneurography
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2026
- U.S. locations
- 2
- States / cities
- Oklahoma City, Oklahoma • Nashville, Tennessee